Full research articles

  • Villa Nova M, Nothnagel L, Thurn M, Travassos PB, Herculano LS, Bittencourt PRS, Novello CR, Bazotte RB, Wacker MG, Bruschi ML; Development study of pectin/Surelease microparticles for the delivery of L-alanyl-L-glutamine dipeptide, Food Hydrocoll. (https://doi.org/10.1016/j.foodhyd.2018.11.038)
  • Feczkó T, Piiper A, Ansar S, Blixt FW, Ashtikar M, Schiffmann S, Ulshöfer T, Parnham MJ, Harel Y, Israel LL, Lellouche JP, Wacker MG; Stimulating brain recovery after stroke using theranostic albumin nanocarriers loaded with nerve growth factor in combination therapy, J. Control. Rel. 293: 63-72 (https://doi.org/10.1016/j.jconrel.2018.11.017)
  • Nothnagel L and Jung F, Rossmanith T, Thurn M, Ashtikar M, Geisslinger G, Parnham MJ, Wacker MG; Predictive PBPK modeling as a tool in the formulation of the drug candidate TMP-001, Eur. J. Pharm. Biopharm. (https://doi.org/10.1016/j.ejpb.2018.11.012)
  • Jung F and Nothnagel L, Gao F, Thurn M, Vogel V, Wacker MG; A comparison of two biorelevant in vitro drug release methods for nanotherapeutics based on advanced physiologically-based pharmacokinetic modelling, Eur. J. Pharm. Biopharm. 127: 462-470 (https://doi.org/10.1016/j.ejpb.2018.03.010)
  • Janas C, Kirsamer L, Mast MP, Agioni C, Gao F, Mäntele W, Dressman J, Wacker MG; The dispersion releaser technology is an effective method to test the drug release from nanosized carriers, Eur. J. Pharm. Biopharm. 115: 73-83 (https://doi.org/10.1016/j.ejpb.2017.02.006)
  • Beyer S and Xie L, Schmidt M, de Bruin N, Ashtikar M, Rüschenbaum S, Lange CM, Vogel V, Mäntele W, Parnham MJ, Wacker MG; Optimizing novel implant formulations for the prolonged release of biopharmaceuticals using in vitro and in vivo imaging techniques, J. Control. Release, 10(235): 352-364 (https://doi.org/10.1016/j.jconrel.2016.06.013)
  • Janas C, Mostaphaoui Z, Schmiederer L, Bauer J, Wacker MG; Novel polymeric micelles for drug delivery: Material characterization and formulation screening, Int. J. Pharm. 509(1-2): 197-207 (https://doi.org/10.1016/j.ijpharm.2016.05.029)
  • Beyer S, Moosmann A, Kahnt AS, Ulshöfer T, Parnham MJ, Ferreirós N, Wacker MG; Drug release and targeting: The versatility of polymethacrylate nanoparticles for peroral administration revealed by using an optimized in vitro-toolbox, Pharm. Res. 32(12): 3986-3998 (https://doi.org/10.1007/s11095-015-1759-2)
  • Villa Nova M, Janas C, Schmidt M, Ulshöfer T, Gräfe S, Schiffmann S, de Bruin N, Wiehe A, Albrecht V, Parnham MJ, Bruschi ML, Wacker MG; Nanocarriers for photodynamic therapy – Rational formulation design and medium-scale manufacture, Int. J. Pharm. 491(1-2): 250-260 (https://doi.org/10.1016/j.ijpharm.2015.06.024)
  • Xie L, Beyer S, Vogel V, Wacker MG, Mäntele W; Assessing the Drug Release from Nanoparticles: Overcoming the Shortcomings of Dialysis by Using Novel Optical Techniques and a Mathematical Model, Int. J. Pharm. 488(1-2): 108-119 (https://doi.org/10.1016/j.ijpharm.2015.03.080)
  • Beyer S, Xie L, Graefe S, Vogel V, Dietrich K, Wiehe A, Albrecht V, Maentele W, Wacker MG; Bridging Laboratory and Large Scale Production: Preparation and In Vitro-Evaluation of Photosensitizer-Loaded Nanocarrier Devices for Targeted Drug Delivery, Pharm. Res. 32(5): 1714-1726 (https://doi.org/10.1007/s11095-014-1569-y)
  • Wacker MG, Altinok M, Urfels S, Bauer J; Nanoencapsulation of superparamagnetic particles of iron oxide into human serum albumin nanoparticles, Beilstein J. Nanotechnol. 5: 2259-2266 (https://doi.org/10.3762/bjnano.5.235)
  • Gaca S, Reichert S, Multhoff G, Wacker M, Hehlgans S, Botzler C,Gehrmann M, Rödel C, Kreuter J, Rödel F; Targeting by cmHsp70.1-antibody coated and Survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells, J. Control. Release 172(1): 201-206 (https://doi.org/10.1016/j.jconrel.2013.08.020)
  • Hofmann B, Rödl CB, Fischer AS, Maier TJ, Michel AA, Hoffmann M, Rau O, Awwad K, Pellowska M, Wurglics M, Wacker M, Živković A, Fleming I, Schubert-Zsilavecz M, Stark H, Schneider G, Steinhilber D; Molecular pharmacological profile of a novel thiazolinone-based direct and selective 5-lipoxygenase inhibitor, Br. J. Pharmacol. 165(7): 2304-2313 (https://doi.org/10.1111/j.1476-5381.2011.01707.x)
  • Wacker M, Zensi A, Kufleitner J, Ruff A, Schütz J, Stockburger T, Marstaller T, Vogel V; A toolbox for the upscaling of ethanolic human serum albumin (HSA) desolvation, Int. J. Pharm. 414(1-2): 225-232 (https://doi.org/10.1016/j.ijpharm.2011.04.046)
  • Löw K, Wacker M, Wagner S, Langer K, von Briesen H; Targeted human serum albumin nanoparticles for specific uptake in EGFR-expressing colon carcinoma cells, Nanomedicine 7(4): 454-463 (https://doi.org/10.1016/j.nano.2010.12.003)
  • Preuss A, Hackbarth S, Wacker M, Knobloch T, Langer K, Röder B; Comprehensive in vitro investigations on biodegradable photosensitizer-nanoparticle delivery systems, J. Control. Release 148(1): 117-118 (https://doi.org/10.1016/j.jconrel.2010.07.089)
  • Zheng SZ, Löw K, Wacker M, Wiehe A, Wagner S, Langer K, von Briesen H, Zou SQ; Interaction and cytotoxicity of mTHPC and mTHPC complexes in Jurkat cells. Chin. J. Exp. Surg. 27: 13-22. [Article in Chinese]
  • Chen K, Wacker M, Hackbarth S, Ludwig C, Langer K, Roeder B; Photophysical evaluation of mTHPC-loaded HSA nanoparticles as novel PDT delivery systems, J. Photochem. Photobiol. B 101(3): 340-347 (https://doi.org/10.1016/j.jphotobiol.2010.08.006)
  • Wacker M, Chen K, Preuss A, Possemeyer K, Roeder B, Langer K; Photosensitizer loaded HSA nanoparticles I: Preparation and photophysical properties, Int. J. Pharm. 93(1-2): 253-62 (https://doi.org/10.1016/j.ijpharm.2010.11)
  • Chen K, Preuss A, Hackbarth S, Wacker M, Langer K, Roeder B; Novel photosensitizer-protein nanoparticles for photodynamic therapy: photophysical characterization and in vitro investigations, J. Photochem. Photobiol. B 96(1): 66-74 (https://doi.org/0.1016/j.jphotobiol.2009.04.006)

 

Review articles

  • Ashtikar M, Mäder K, Klein M, Wunderlich K, Lozach P-Y, Gao F, Mende S, Strasser C, Dennison T, Marenchino M, Wacker, MG; LOEWE Workshop Particle Characterization in Medicine and Biology, Pharm. Front. 2019;(https://doi.org/10.20900/pf20190002)
  • Nothnagel L, Wacker MG; Mikro- und Nanoarzneiformen in Entwicklung und Qualitätskontrolle – Welche Methoden eignen sich für den Test auf Wirkstofffreisetzung, Pharm. Ind. 10/2018 (Article in German)
  • Nothnagel L, Wacker MG; How to measure release from nanosized carriers, Eur. J. Pharm. Sci. (https://doi.org/10.1016/j.ejps.2018.05.004)
  • Ashtikar M, Wacker MG; Nanotherapeutics for wound healing – Lost in translation?, Adv. Drug Del. Rev. 129, 194-218  (https://10.1016/j.addr.2018.03.005)
  • Wacker MG; Challenges in the drug release testing of next-generation nanomedicines – What do we know?, Mat. Tod. Proc. 2, 214-217 (https://doi.org/10.1016/j.matpr.2017.09.189)
  • Wacker MG, Proykova A, Santos GM; Dealing with nanosafety around the globe – Regulation vs. Innovation, Int. J. Pharm. 509(1-2): 95-106 (https://doi.org/10.1016/j.ijpharm.2016.05.015)
  • Bergs JW, Wacker MG, Hehlgans S, Piiper A, Multhoff G, Rödel C,Rödel F; The role of recent nanotechnology in enhancing the efficacy of radiation therapy, Biochim. Biophys. Acta 1856(1): 130-143 (https://doi.org/10.1016/j.bbcan.2015.06.008)
  • Wacker MG; Hund-Rinke K, Creutzenberg O; Quo vadis Nano? Nanomaterialien in der pharmazeutische Produktentwicklung, Pharm. Ind. 76(7): 1134-1140 (Article in German)
  • Wacker MG; Nanotherapeutics – Product Development Along the ‘Nanomaterial’ Discussion, J. Pharm. Sci. 103(3): 777-784 (https://doi.org/10.1002/jps.23879)
  • Wacker M; Nanocarriers for intravenous injection – The long hard road to the market, Int. J. Pharm. 457(1): 50-62 (https://doi.org/10.1016/j.ijpharm.2013.08.079)

 

Patents and patent applications

  • Wacker MG, Beyer S, Parnham MJ, Maentele W, Vogel V, Xie (Kirsamer) L, Composition Comprising a Biocompatible and Biodegradable Polymer, Nanocarriers and a Drug and Methods of Making and Using the Same, PCT application 2016 (PCT/EP2016/076715)
  • Wacker MG, Janas C; Adapter für die Freisetzung disperser Arzneizubereitungen (Dispersion Releaser), German Patent 2015 (DE102013015522 A1) / PCT application 2014 (PCT/EP2014/002523)
  • Langer K, Wacker M, Röder B, Preuss A, Albrecht V, Gräfe S, Wiehe A, von Briesen H, Löw K, Wagner S; Nanoparticle carrier systems based on human serum albumin for photodynamic therapy (US 2011/0142948 A1)

 

Book chapters

  • Wacker MG, Janas C, Ferreira FS, Vieira FP, ‘Manufacturing and Safety Guidelines for Manufactured Nanomaterials in Pharmaceutics’ in Sarmento B and das Neves J (ed), ‘Biomedical applications of functionalized nanomaterials‘ (1st edn), Elsevier Publishing Group (Netherlands) (https://doi.org/10.1016/B978-0-323-50878-0.00021-5)
  • Wacker MG, ‘Nanomedicines – A Scientific Toy or an Emerging Market?‘ in Vauthier C and Ponchel G (ed), ‘Polymer nanoparticles for nanomedicines: A Guide for Design, Preparation and Development’ (1st edn), Springer International (Switzerland) (https://doi.org/10.1007/978-3-319-41421-8_18)
  • Wacker MG, ‘Suspensionen – Parenteralia, Ophthalmika und perorale Suspensionen: Teilchengrößen-wachstum, Stabilität, Freisetzung‘ in Stieneker F (ed), ‘Partikel in der Pharmaproduktion: Messtechnik – Detektion und Charakterisierung – Regulatorische Anforderungen‘ (1st edn), Editio Canto Verlag (Germany)

 

Abstracts and presentations

  • Wacker MG (2018); Nanotechnology in translation – Define, design, produce!, Institute of Materials and Environmental Chemistry/Hungarian Academy of Sciences, Budapest (Hungary)
  • Wacker MG (2018); Challenges in the drug release testing of next-generation nanomedicines, CRS Indian Chapter Meeting, Mumbai (India)
  • Wacker MG (2018); Advances in Nanosized Drug Delivery – Lost in Translation?, LOSAN Drug Delivery Conference, Frankfurt (Germany)
  • Wacker MG (2017); Safety & Regulatory Aspects of Nanomedicines, National University of Singapore Workshop, Singapore
  • Wacker MG (2017); Challenges in the drug release testing of next-generation nanomedicines, FIP/USP/AAPS workshop, Rockville (USA)
  • Wacker MG (2016); Designing nanocarriers for drug delivery, NRW-Nanokonferenz, Münster (Germany)
  • Wacker MG (2016); Challenges in the drug release testing of next generation nanomedicines, NanoBioMedizin Meeting, Frankfurt (Germany)
  • Nothnagel L, Thurn M, Wacker MG (2016); DoE-based development and in vitro drug release testing of TMP-001 loaded nanocarriers, GPEN Meeting, Lawrence (USA)
  • Jablonka L, Thurn M, Wacker MG (2016); In vitro drug release testing of liposomal temoporfin formulations with the dispersion releaser technology, GPEN Meeting, Lawrence (USA)
  • Wacker MG (2016), Designing Nanomedicines for the Market, DDF Summit, Berlin (Germany)
  • Wacker MG (2016), Assessing the drug release from nanocarriers: when, why and how?, PT Indonesia Workshop, Jakarta (Indonesia)
  • Wacker MG (2016), Assessing the drug release from nanocarriers: when, why and how?, Matrix Analytical Technologies Workshop, Kuala Lumpur (Malaysia)
  • Wacker MG (2016), Assessing the drug release from nanocarriers: when, why and how?, LOSAN Drug Delivery Conference, Frankfurt (Germany)
  • Wacker MG (2015), Die neue Nanomedizin – Von der Idee zum Produkt, NanoBioMedizin Meeting, Frankfurt, Germany
  • Wacker MG (2015), Nanocarriers for Drug Delivery – Rational Formulation Design, 1st International Symposium on Drug Delivery Systems, Maringá, Brazil
  • Wacker MG (2015), Parenteralia, Ophthalmika und perorale Suspensionen – Stabilität, Teilchengrößenwachstum und Freisetzung, FAH Workshop – Pharmaproduktion und Partikel, Bonn, Germany
  • Wacker MG (2015), Nanocarriers for Cancer Therapy – Rational Formulation Design, Evonik-LOSAN Workshop, Darmstadt, Germany
  • Wacker MG (2015), Nanocarriers for Drug Delivery – Rational Formulation Design, DDF Global Summit, Düsseldorf, Germany
  • Wacker MG (2014), Rational Formulation Design – Nanomedizin mal anders!, DPhG, Freiburg, Germany
  • Janas C, Dressman JB, Wacker MG (2014), The Dispersion Releaser: An Optimal Tool for Selection of Colloidal Dosage Forms, GPEN Meeting, Helsinki, Finland
  • Beyer S, Gräfe S, Albrecht V, Wacker MG (2014), Accepting the Challenge of Scale-up – A New Approach for the Targeted Treatment of Colon Cancer based on Nanoparticles overcomes the Limitations of Batch Size, Controlled Release Socienty Annual Meeting, Chicago, USA
  • Wacker MG (2014), Rational Formulation Design – Nanomedizin mal anders!, Neue Potentiale für die Nanotechnologie in der Medizin, Darmstadt, Germany
  • Wacker MG, Parnham MJ (2014), Achieving a Good Working Relationship with an Academic Research Organization, Drug Delivery & Formulation Americas Summit, San Diego, USA
  • Wacker M (2013); Nanocarrier – Entwicklung und Optimierung innovativer Arzneistoffträger, PharmaForum Hessen 2013, Mainz, Germany
  • Wacker M (2013) Nanocarrier – Trends in Modern Formulation Development, LOSAN Innovative Dosage Forms in Development and Production Workshop, Essen (Germany)
  • Wacker M (2011); Nanopartikel – Eine neue Alternative in der peroralen Arzneistoffformulierung, Pharmaforum 2011 Saarland, St. Ingbert, Germany
  • Wacker M, Ruff A, Schütz J, Vogel V (2011); Upscaling of ethanolic human serum albumin (HSA) desolvation, 38th Annual Meeting and Exposition of the Controlled Release Society 2011, National Harbor, USA